Singapore's Temasek-backed entity to acquire 16pct stake in Ayala's healthcare arm
In August 2024, Reuters reported that the Ayala Corp was keen on selling a minority stake in its healthcare business, which would value the company at up to US$500 million.
AC Health did not specify a value for the 16 per cent stake.
Global investors are increasingly drawn to Southeast Asia's healthcare sector, wagering on the region's rising prosperity, aging demographics, and the industry's resilience in a challenging economic climate.
In November 2023, Malaysian conglomerate Sime Darby and Australia's Ramsay Health Care agreed to sell their equal ownership joint venture for 5.7 billion ringgit (US$1.34 billion).
Established in 2015, AC Health has expanded its portfolio to include the Generika and St. Joseph Drug pharmacy chains, as well as pharmaceutical importer and distributor IE Medica and MedEthix, according to its websites.
It aims to expand its network to at least 10 hospitals, 300 clinics and 1,150 pharmacies.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New Straits Times
12 minutes ago
- New Straits Times
Singapore million-dollar flat sales hit record in Q2
SINGAPORE: A record number of Singapore public housing units were sold for S$1 million (US$780,000) or more in the June quarter, a private data provider said on Wednesday, taking the number of high-value sales in the first half of the year to almost 75 per cent of the 2024 total. Eight out of 10 Singapore citizens live in public housing built and sold by the government, and its affordability is a key issue for policymakers alongside high living costs. According to real estate agency OrangeTee Group, a record 415 apartments were sold at prices above S$1 million in the second quarter, a 75.8 per cent increase compared to the same period in 2024, after 348 sales in the first quarter. Sales of million-dollar flats this year are "on track to exceed last year's full-year record of 1,035 units", OrangeTee Group analysts said in a report. The most expensive resale in the quarter was a 122 sqm (1,313 sqft) apartment which sold for S$1,658,888, the report showed. Overall, resale prices rose 0.9 per cent on a quarterly basis, according to earlier government data. While prices have now risen for 21 straight quarters, it was the smallest rise since the second quarter of 2020, during the COVID-19 pandemic. OrangeTee Group analysts expect public home resale prices "to rise modestly for the remainder of the year, driven by our stable economic fundamentals and declining interest rates", forecasting an annual rise of 4 per cent to 5.5 per cent. Last year, the government sought to cool the market by reducing how much buyers can borrow from the state. After a better-than-expected first half performance, the government on Tuesday raised its GDP growth forecast for 2025 to 1.5 per cent to 2.5 per cent from 0.0 per cent to 2 per cent, having cut the forecast earlier this year after the announcement of US tariffs.
New Straits Times
12 minutes ago
- New Straits Times
Palm oil unpacked: Separate fact from fiction on cholesterol
A recent national survey commissioned by Pertubuhan Transformasi Dayak, and conducted by independent research firm Green Zebras, found that 37 per cent of Malaysians believe palm oil causes high cholesterol. This finding highlights a widespread misconception that deserves clarification through better public health communication and science-based education. Palm oil is often misunderstood and wrongly assumed to contribute to high cholesterol and heart disease. However, it is a plant-based oil and contains no dietary cholesterol. The assumption that it is harmful likely stems from outdated or oversimplified views on dietary fats. What makes palm oil's consumption so compelling is that research supports its nutritional benefits. A comprehensive review published in the United States' National Library of Medicine in 2023 analysed 31 studies involving nearly 2,400 participants. The findings showed that palm oil does not increase the risk of cardiovascular disease when compared to other commonly used vegetable oils such as soybean, olive, or sunflower oil. The study also found no significant negative effects on cholesterol levels in healthy individuals. Palm oil has a balanced fatty acid profile, with about 50 per cent saturated fat, 40 per cent monounsaturated (heart-healthy) fats and 10 per cent polyunsaturated fats. This composition can help reduce LDL (bad) cholesterol. Moreover, palm oil is naturally trans-fat free and does not undergo the industrial hydrogenation process that may create trans fats in other oils. Trans fats are typically produced by partially hydrogenating liquid vegetable oils to extend shelf life and change texture. This process alters the fat's structure and introduces well-documented health risks. Palm oil, by contrast, is naturally semi-solid at room temperature and stable during high-heat cooking, eliminating the need for hydrogenation. It is also important to recognise that high cholesterol is usually the result of a combination of factors. These include poor diet coupled with a lack of physical activity, smoking, stress, inadequate sleep, or genetics. Singling out palm oil oversimplifies a complex issue and distracts from the more significant contributors to cardiovascular risk. Palm oil is widely used in Malaysian households. It is locally produced, widely used, and economically important. It is also affordable and accessible to the majority of households. When used in moderation as part of a balanced diet, palm oil does not pose a health risk. As we continue to encourage healthy lifestyles, we must also ensure that our public messaging reflects current scientific understanding. Outdated assumptions should not guide how we view food and health. Instead, we must foster a more informed, balanced conversation around nutrition. As a doctor, I urge Malaysians to shift the focus from blame to balance. We need to look at our overall lifestyle, including our diets, activity levels, stress, and habits, rather than placing the blame on a single ingredient. When we ground our decisions in science instead of speculation, we make real progress in improving heart health. It is equally important for policymakers, educators, and healthcare professionals to come together and strengthen public understanding. Health advice must be based on evidence, not myths.
New Straits Times
42 minutes ago
- New Straits Times
Global investors flock to ex-US markets for better growth, valuations
KUALA LUMPUR: Global ex-US equity funds received their biggest inflows in more than four-and-a-half years in July, as investors redirected capital away from the United States on concerns over the economy, stretched stock values, and a weakening dollar. These funds began seeing inflows earlier this year as President Donald Trump's economic policies hurt the appeal of US markets. But the steep gains in July suggest a sustained shift towards diversification, particularly into Europe and emerging markets benefitting from easier monetary conditions and improved growth prospects. According to LSEG Lipper, global ex-U.S. equity funds secured an inflow of US$13.6 billion in July, the highest since December 2021. In contrast, US-focused equity funds saw US$6.3 billion in outflows, marking their third straight month of redemptions. "While tariff de-escalation was a tailwind in the second quarter, unresolved trade negotiations and policy deadlines approaching in the early third quarter pose ongoing risks," Shelton Capital Management Chief Investment Officer Derek Izuel said. "Persistent uncertainty could reignite flows out of US equities, particularly if growth differentials continue to narrow or the Federal Reserve maintains restrictive monetary policy." The divergence in performance has been another key driver of outflows from US equities, with the MSCI Asia Pacific ex-Japan index up around 14 per cent and the MSCI Europe index gaining more than 19 per cent this year, outpacing the S&P 500's 7.2 per cent rise. Furthermore, the dollar has declined about 10 per cent this year, amplifying returns for US investors from international markets. Jim Smigiel, chief Investment Officer at SEI, said that while global diversification remains a key focus, it is too soon to tell if recent flows mark a sustained shift. "We see this recent trend as more of a strategic rebalancing to neutral positioning from a geographic perspective and less of an adoption of any underweight to the US," he said. The forward 12-month price-to-earnings ratio of the MSCI US index stood at 22.6, much higher than MSCI Asia's 14.4, MSCI Europe's 14.2 and MSCI World's 19.7.
